Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | XDH | P47989 | 5/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | THRA | P10827 | 2/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.43 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31685938 | 0.88 | MAPK1 (0.51) | HTTMAPK1XDHKDM4EALDH1A1 | |
| SCHEMBL7191977 | 0.83 | HTT (0.47) | HTTMAPK1XDHKDM4EALDH1A1 | |
| SCHEMBL8478888 | 0.83 | PTPN11 (0.51) | KDM4EALDH1A1HSD17B10PTPN11S1PR3 | |
| SCHEMBL9038729 | 0.82 | MAPK1 (0.57) | HTTMAPK1XDHKDM4EALDH1A1 | |
| SCHEMBL7185662 | 0.82 | HTT (0.46) | HTTMAPK1XDHKDM4EALDH1A1 | |
| SCHEMBL13392323 | 0.82 | ALDH1A1 (0.45) | HTTKDM4EALDH1A1PTPN11S1PR3 | |
| Hydrochloric Acid SCHEMBL9038923 | 0.81 | MAPK1 (0.56) | HTTMAPK1XDHKDM4EALDH1A1 | |
| SCHEMBL20472655 | 0.81 | PTPN11 (0.63) | ALDH1A1PTPN11S1PR3 | |
| SCHEMBL20522189 | 0.80 | TSHR (0.56) | KDM4EHSD17B10PTPN11S1PR3 | |
| SCHEMBL568543 | 0.78 | HTT (0.74) | HTTMAPK1KDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1268494-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | Merck Frosst Canada & Co. (CA) | 2003-01-02 | — | — | EP | disclosed |
| US-6498151-B2 | PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS | MERCK FROSST CANADA & CO. (CA) | 2002-12-24 | — | — | US | disclosed |
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | MERCK FROSST CANADA LTD. (CA) | 2002-07-11 | — | — | US | disclosed |
| WO-2001070753-A1 | SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091104-A1 | Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors | PTPRF, PTPRS, PTPRO | HTT 1549/4885MAPK1 324/4885XDH 516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.